Improvement of surgical results for pancreatic cancer

The Lancet Oncology

Volumn 14, Issue 11, 2013, Pages

  Hartwig, Werner ^a   Werner, Jens ^a   Jäger, Dirk ^a   Debus, Jürgen ^a   Büchler, Markus W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CAPECITABINE; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SOMATOSTATIN DERIVATIVE;

ADJUVANT THERAPY; ADVANCED CANCER; ANASTOMOSIS; ASYMPTOMATIC DISEASE; BILIARY TRACT DRAINAGE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DISTAL PANCREATECTOMY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HOSPITAL CARE; HUMAN; LAPAROSCOPIC PANCREATECTOMY; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS FISTULA; PANCREAS RESECTION; PANCREAS SURGERY; PANCREATIC ANASTOMOSIS; PANCREATICODUODENECTOMY; PANCREATICOENTERIC ANASTOMOSIS; PANCREATICOGASTROSTOMY; PANCREATICOJEJUNOSTOMY; PATIENT SAFETY; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PRECANCER; PREOPERATIVE CARE; PRIORITY JOURNAL; REOPERATION; RETROPERITONEAL PERIPANCREATIC TISSUE TRANSECTION; REVIEW; RISK FACTOR; SURGEON; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; UNSPECIFIED SIDE EFFECT; VASCULAR SURGERY;

ANIMALS; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84884683546     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70172-4     Document Type: Review

References (80)

1. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073-1081.
2. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-277.
3. Hartwig W, Hackert T, Hinz U, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 2011, 254:311-319.
4. Mayo SC, Nathan H, Cameron JL, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 2012, 118:2674-2681.
5. Konstantinidis IT, Warshaw AL, Allen JN, et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?. Ann Surg 2013, 257:731-736.
6. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M Pancreatic cancer. Lancet 2011, 378:607-620.
7. Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012, 10:703-713.
8. Imamura M, Doi R, Imaizumi T, et al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 2004, 136:1003-1011.
9. Lygidakis NJ, Singh G, Bardaxoglou E, et al. Mono-bloc total spleno-pancreaticoduodenectomy for pancreatic head carcinoma with portal-mesenteric venous invasion. A prospective randomized study. Hepatogastroenterology 2004, 51:427-433.
10. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William TL, Linehan DC Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009, 16:1727-1733.
11. Hartwig W, Schneider L, Diener MK, Bergmann F, Büchler MW, Werner J Preoperative tissue diagnosis for tumours of the pancreas. Br J Surg 2009, 96:5-20.
12. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012, 142:796-804.
13. Wasif N, Bentrem DJ, Farrell JJ, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer 2010, 116:3369-3377.
14. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012, 12:183-197.
15. Rodriguez JR, Salvia R, Crippa S, et al. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 2007, 133:72-79.
16. Maguchi H, Tanno S, Mizuno N, et al. Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas: a multicenter study in Japan. Pancreas 2011, 40:364-370.
17. Fritz S, Klauss M, Bergmann F, et al. Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg 2012, 256:313-320.
18. Correa-Gallego C, Ferrone CR, Thayer SP, Wargo JA, Warshaw AL, Fernandez-del Castillo C Incidental pancreatic cysts: do we really know what we are watching?. Pancreatology 2010, 10:144-150.
19. Salvia R, Malleo G, Marchegiani G, et al. Pancreatic resections for cystic neoplasms: from the surgeon's presumption to the pathologist's reality. Surgery 2012, 152(3 suppl 1):S135-S142.
20. Uehara H, Nakaizumi A, Ishikawa O, et al. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 2008, 57:1561-1565.
21. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS National failure to operate on early stage pancreatic cancer. Ann Surg 2007, 246:173-180.
22. Mann CD, Palser T, Briggs CD, et al. A review of factors predicting perioperative death and early outcome in hepatopancreaticobiliary cancer surgery. HPB (Oxford) 2010, 12:380-388.
23. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005, 138:8-13.
24. Xiong JJ, Altaf K, Mukherjee R, et al. Systematic review and meta-analysis of outcomes after intraoperative pancreatic duct stent placement during pancreaticoduodenectomy. Br J Surg 2012, 99:1050-1061.
25. Motoi F, Egawa S, Rikiyama T, Katayose Y, Unno M Randomized clinical trial of external stent drainage of the pancreatic duct to reduce postoperative pancreatic fistula after pancreaticojejunostomy. Br J Surg 2012, 99:524-531.
26. Topal B, Fieuws S, Aerts R, et al. Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial. Lancet Oncol 2013, 14:655-662.
27. Diener MK, Seiler CM, Rossion I, et al. Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet 2011, 377:1514-1522.
28. Carter TI, Fong ZV, Hyslop T, et al. A dual-institution randomized controlled trial of remnant closure after distal pancreatectomy: does the addition of a falciform patch and fibrin glue improve outcomes?. J Gastrointest Surg 2013, 17:102-109.
29. Olah A, Issekutz A, Belagyi T, Hajdu N, Romics L Randomized clinical trial of techniques for closure of the pancreatic remnant following distal pancreatectomy. Br J Surg 2009, 96:602-607.
30. Frozanpor F, Lundell L, Segersvard R, Arnelo U The effect of prophylactic transpapillary pancreatic stent insertion on clinically significant leak rate following distal pancreatectomy: results of a prospective controlled clinical trial. Ann Surg 2012, 255:1032-1036.
31. Gurusamy KS, Koti R, Fusai G, Davidson BR Somatostatin analogues for pancreatic surgery. Cochrane Database Syst Rev 2012, 6. CD008370.
32. Gans SL, van Westreenen HL, Kiewiet JJ, Rauws EA, Gouma DJ, Boermeester MA Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula. Br J Surg 2012, 99:754-760.
33. Diener MK, Fitzmaurice C, Schwarzer G, et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2011, 5. CD006053.
34. Kawai M, Tani M, Hirono S, et al. Pylorus ring resection reduces delayed gastric emptying in patients undergoing pancreatoduodenectomy: a prospective, randomized, controlled trial of pylorus-resecting versus pylorus-preserving pancreatoduodenectomy. Ann Surg 2011, 253:495-501.
35. Tani M, Terasawa H, Kawai M, et al. Improvement of delayed gastric emptying in pylorus-preserving pancreaticoduodenectomy: results of a prospective, randomized, controlled trial. Ann Surg 2006, 243:316-320.
36. van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010, 362:129-137.
37. Eshuis WJ, van der Gaag NA, Rauws EA, et al. Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage. Ann Surg 2010, 252:840-849.
38. Fang Y, Gurusamy KS, Wang Q, et al. Pre-operative biliary drainage for obstructive jaundice. Cochrane Database Syst Rev 2012, 9. CD005444.
39. Venkat R, Edil BH, Schulick RD, Lidor AO, Makary MA, Wolfgang CL Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg 2012, 255:1048-1059.
40. Kooby DA, Hawkins WG, Schmidt CM, et al. A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate?. J Am Coll Surg 2010, 210:779-787.
41. Kendrick ML, Cusati D Total laparoscopic pancreaticoduodenectomy: feasibility and outcome in an early experience. Arch Surg 2010, 145:19-23.
42. Joseph B, Morton JM, Hernandez-Boussard T, Rubinfeld I, Faraj C, Velanovich V Relationship between hospital volume, system clinical resources, and mortality in pancreatic resection. J Am Coll Surg 2009, 208:520-527.
43. Ghaferi AA, Birkmeyer JD, Dimick JB Variation in hospital mortality associated with inpatient surgery. N Engl J Med 2009, 361:1368-1375.
44. Büchler MW, Wagner M, Schmied BM, Uhl W, Friess H, Z'graggen K Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg 2003, 138:1310-1314.
45. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002, 346:1128-1137.
46. Birkmeyer JD, Sun Y, Wong SL, Stukel TA Hospital volume and late survival after cancer surgery. Ann Surg 2007, 245:777-783.
47. Gooiker GA, van Gijn W, Wouters MW, Post PN, van de Velde CJ, Tollenaar RA Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg 2011, 98:485-494.
48. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL Surgeon volume and operative mortality in the United States. N Engl J Med 2003, 349:2117-2127.
49. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer 2007, 110:1227-1234.
50. Finks JF, Osborne NH, Birkmeyer JD Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 2011, 364:2128-2137.
51. Lemmens VE, Bosscha K, van der Schelling G, Brenninkmeijer S, Coebergh JW, de Hingh IH Improving outcome for patients with pancreatic cancer through centralization. Br J Surg 2011, 98:1455-1462.
52. Butturini G, Stocken DD, Wente MN, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008, 143:75-83.
53. Brennan MF, Kattan MW, Klimstra D, Conlon K Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 2004, 240:293-298.
54. Isaji S, Kawarada Y, Uemoto S Classification of pancreatic cancer: comparison of Japanese and UICC classifications. Pancreas 2004, 28:231-234.
55. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 2007, 110:738-744.
56. Wasif N, Bentrem DJ, Farrell JJ, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer 2010, 116:3369-3377.
57. Gillen S, Schuster T, Meyer Zum BC, Friess H, Kleeff J Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7:e1000267.
58. Chua TC, Saxena A Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. J Gastrointest Surg 2010, 14:1442-1452.
59. Zhou Y, Zhang Z, Liu Y, Li B, Xu D Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg 2012, 36:884-891.
60. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008, 15:165-174.
61. Iqbal N, Lovegrove RE, Tilney HS, et al. A comparison of pancreaticoduodenectomy with extended pancreaticoduodenectomy: a meta-analysis of 1909 patients. Eur J Surg Oncol 2009, 35:79-86.
62. Jamieson NB, Foulis AK, Oien KA, et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg 2010, 251:1003-1010.
63. Sanjay P, Takaori K, Govil S, Shrikhande SV, Windsor JA 'Artery-first' approaches to pancreatoduodenectomy. Br J Surg 2012, 99:1027-1035.
64. Hackert T, Werner J, Weitz J, Schmidt J, Büchler MW Uncinate process first-a novel approach for pancreatic head resection. Langenbecks Arch Surg 2010, 395:1161-1164.
65. Pessaux P, Rosso E, Panaro F, et al. Preliminary experience with the hanging maneuver for pancreaticoduodenectomy. Eur J Surg Oncol 2009, 35:1006-1010.
66. Reddy S, Wolfgang CL, Cameron JL, et al. Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival. Ann Surg 2009, 250:282-287.
67. Billings BJ, Christein JD, Harmsen WS, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up?. J Gastrointest Surg 2005, 9:1059-1066.
68. Schmidt CM, Glant J, Winter JM, et al. Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma. Surgery 2007, 142:572-578.
69. Mollberg N, Rahbari NN, Koch M, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg 2011, 254:882-893.
70. Hartwig W, Hackert T, Hinz U, et al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg 2009, 250:81-87.
71. Burdelski CM, Reeh M, Bogoevski D, et al. Multivisceral resections in pancreatic cancer: identification of risk factors. World J Surg 2011, 35:2756-2763.
72. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358:1576-1585.
73. Neoptolemos JP, Stocken DD, Tudur SC, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009, 100:246-250.
74. Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009, 101:908-915.
75. Neuhaus P, Riess H, Post S, et al. CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). Proc Am Soc Clin Oncol 2008, 26(suppl). [15S].
76. Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012, 308:147-156.
77. Stocken DD, Büchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005, 92:1372-1381.
78. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008, 19:1592-1599.
79. Schmidt J, Abel U, Debus J, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 2012, 30:4077-4083.
80. Strobel O, Hartwig W, Hackert T, et al. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol 2013, 20:964-972.